Tazemetostat Hydrobromide Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as EPIZYME INC. It is marketed under 1 brand name, including TAZVERIK. Available in 1 different strength, such as EQ 200MG BASE, and administered through 1 route including TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"100486","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US10155002B2","cleaned_patent_number":"10155002","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2018-12-18","legal_status":"Granted"} US10155002B2 18 Dec, 2018 Granted 12 Sep, 2031
{"application_id":"139439","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US12168015B2","cleaned_patent_number":"12168015","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2024-12-17","legal_status":"Granted"} US12168015B2 Molecular Formulation 17 Dec, 2024 Granted 12 Sep, 2031
{"application_id":"139438","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US12168016B2","cleaned_patent_number":"12168016","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2024-12-17","legal_status":"Granted"} US12168016B2 17 Dec, 2024 Granted 12 Sep, 2031
{"application_id":"100772","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"13dfaeaa07ec4d04a7a7","publication_number":"US8691507B2","cleaned_patent_number":"8691507","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2014-04-08","legal_status":"Granted"} US8691507B2 08 Apr, 2014 Granted 12 Sep, 2031
{"application_id":"100561","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US8765732B2","cleaned_patent_number":"8765732","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2014-07-01","legal_status":"Granted"} US8765732B2 01 Jul, 2014 Granted 12 Sep, 2031
{"application_id":"100773","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"13dfaeaa07ec4d04a7a7","publication_number":"US8895245B2","cleaned_patent_number":"8895245","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2014-11-25","legal_status":"Granted"} US8895245B2 25 Nov, 2014 Granted 12 Sep, 2031
{"application_id":"100562","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US9090562B2","cleaned_patent_number":"9090562","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2015-07-28","legal_status":"Granted"} US9090562B2 Molecular Formulation 28 Jul, 2015 Granted 12 Sep, 2031
{"application_id":"100774","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"13dfaeaa07ec4d04a7a7","publication_number":"US9175331B2","cleaned_patent_number":"9175331","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2015-11-03","legal_status":"Granted"} US9175331B2 03 Nov, 2015 Granted 12 Sep, 2031
{"application_id":"100775","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"13dfaeaa07ec4d04a7a7","publication_number":"US9333217B2","cleaned_patent_number":"9333217","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2016-05-10","legal_status":"Granted"} US9333217B2 10 May, 2016 Granted 12 Sep, 2031
{"application_id":"100728","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"13dfaeaa07ec4d04a7a7","publication_number":"US9334527B2","cleaned_patent_number":"9334527","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2016-05-10","legal_status":"Granted"} US9334527B2 10 May, 2016 Granted 12 Sep, 2031
{"application_id":"100564","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US9549931B2","cleaned_patent_number":"9549931","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2017-01-24","legal_status":"Granted"} US9549931B2 24 Jan, 2017 Granted 12 Sep, 2031
{"application_id":"100565","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US9855275B2","cleaned_patent_number":"9855275","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2018-01-02","legal_status":"Granted"} US9855275B2 02 Jan, 2018 Granted 12 Sep, 2031
{"application_id":"100776","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"13dfaeaa07ec4d04a7a7","publication_number":"US9949999B2","cleaned_patent_number":"9949999","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2018-04-24","legal_status":"Granted"} US9949999B2 24 Apr, 2018 Granted 12 Sep, 2031
{"application_id":"100566","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US10420775B2","cleaned_patent_number":"10420775","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2019-09-24","legal_status":"Granted"} US10420775B2 24 Sep, 2019 Granted 12 Sep, 2031
{"application_id":"139436","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US12161645B2","cleaned_patent_number":"12161645","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-09-12","publication_date":"2024-12-10","legal_status":"Patented case"} US12161645B2 10 Dec, 2024 Patented case 12 Sep, 2031
{"application_id":"100567","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US11052093B2","cleaned_patent_number":"11052093","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-04-13","publication_date":"2021-07-06","legal_status":"Granted"} US11052093B2 Molecular Formulation 06 Jul, 2021 Granted 13 Apr, 2032
{"application_id":"100574","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"6819dab5772b45f29d05","publication_number":"US10245269B2","cleaned_patent_number":"10245269","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-04-11","publication_date":"2019-04-02","legal_status":"Granted"} US10245269B2 02 Apr, 2019 Granted 11 Apr, 2033
{"application_id":"100620","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"6819dab5772b45f29d05","publication_number":"US10821113B2","cleaned_patent_number":"10821113","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-04-11","publication_date":"2020-11-03","legal_status":"Patented case"} US10821113B2 Molecular Formulation 03 Nov, 2020 Patented case 11 Apr, 2033
{"application_id":"100621","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"6819dab5772b45f29d05","publication_number":"US11491163B2","cleaned_patent_number":"11491163","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-04-11","publication_date":"2022-11-08","legal_status":"Patented case"} US11491163B2 08 Nov, 2022 Patented case 11 Apr, 2033
{"application_id":"100618","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"6819dab5772b45f29d05","publication_number":"US9394283B2","cleaned_patent_number":"9394283","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-04-11","publication_date":"2016-07-19","legal_status":"Granted"} US9394283B2 Molecular Formulation 19 Jul, 2016 Granted 11 Apr, 2033
{"application_id":"100560","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"1ae941613b084235a7ed","publication_number":"US8410088B2","cleaned_patent_number":"8410088","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-01-23","publication_date":"2013-04-02","legal_status":"Granted"} US8410088B2 Molecular Formulation 02 Apr, 2013 Granted 23 Jan, 2034
{"application_id":"139437","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"","publication_number":"US12162865B2","cleaned_patent_number":"12162865","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-05-21","publication_date":"2024-12-10","legal_status":"Granted"} US12162865B2 10 Dec, 2024 Granted 21 May, 2034
{"application_id":"100625","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"99a7a60b98e34191a7de","publication_number":"US9688665B2","cleaned_patent_number":"9688665","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-08-22","publication_date":"2017-06-27","legal_status":"Granted"} US9688665B2 27 Jun, 2017 Granted 22 Aug, 2034
{"application_id":"100480","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"b4f441c88bbe416fbf1a","publication_number":"US10369155B2","cleaned_patent_number":"10369155","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-10-16","publication_date":"2019-08-06","legal_status":"Granted"} US10369155B2 06 Aug, 2019 Granted 16 Oct, 2035
{"application_id":"100461","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"b4f441c88bbe416fbf1a","publication_number":"US9889138B2","cleaned_patent_number":"9889138","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-10-16","publication_date":"2018-02-13","legal_status":"Granted"} US9889138B2 13 Feb, 2018 Granted 16 Oct, 2035
{"application_id":"100785","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"13d864e63930425dabbc","publication_number":"US10786511B2","cleaned_patent_number":"10786511","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-12-19","publication_date":"2020-09-29","legal_status":"Patented case"} US10786511B2 Formulation 29 Sep, 2020 Patented case 19 Dec, 2035
{"application_id":"100800","ingredient":"TAZEMETOSTAT HYDROBROMIDE","trade_name":"TAZVERIK","family_id":"13d864e63930425dabbc","publication_number":"US20210060030A1","cleaned_patent_number":"12168014","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-05-03","publication_date":"2024-12-17","legal_status":"Pending"} US12168014B2 17 Dec, 2024 Pending 03 May, 2038

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Tazemetostat Hydrobromide

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.